FinanceNewsAPI
Moderna (MRNA) Stock Surges 14% on Hantavirus Vaccine. Here’s What Investors Should Know - TipRanks
Overview
Moderna shares jumped about 14% after investors reacted to early-stage work on a hantavirus vaccine, reflecting renewed enthusiasm for mRNA applications. But the initial rally largely faded midday as health officials downplayed the likelihood of a broader pandemic and peers such as Inovio and Novavax pared gains. Investors should still weigh the preliminary nature of the hantavirus program, regulatory uncertainty, and the company’s recent large patent-settlement costs when assessing risk.
Entities
ORGModernaORGTipRanks
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 4 · Connections: 3
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.